Ge Long Hui A P P·2026-03-30 17:00Core Viewpoint - 康龙化成 reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.2% to 1.664 billion RMB [1] Group 1: Financial Performance - The company announced a proposed final dividend of 2.0 RMB per 10 shares (tax included) for the year ending December 31, 2025 [1] - The revenue growth of 14.82% indicates strong operational performance despite the decline in net profit [1] - The new signed orders increased by over 14% year-on-year, indicating a positive trend in business development [1] Group 2: Strategic Initiatives - The company emphasizes a customer-centric service philosophy and leverages an integrated service platform to meet diverse global client needs [1] - Significant achievements were noted in expanding the client base, particularly with large pharmaceutical companies [1] - The company is actively implementing market strategies tailored to the Chinese market, contributing to rapid growth in client business [1] Group 3: Future Outlook - The company anticipates a revenue growth of 12% to 18% for the year 2026 based on new signed orders and business trends [1] - The company maintains industry leadership in small molecule fields while also achieving rapid development in new molecular type projects [1]